Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages.

Atherosclerosis - 1 Jan 2017

Adorni Maria Pia, Cipollari Eleonora, Favari Elda, Zanotti Ilaria, Zimetti Francesca, Corsini Alberto, Ricci Chiara, Bernini Franco, Ferri Nicola

Abstract excerpt

BACKGROUND AND AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) may have extra-hepatic effects on cholesterol homeostasis of vascular macrophages. In this study, we aimed to investigate PCSK9 role on the anti-atherogenic process of ATP binding cassette transporter A1 (Abca1)-mediated cholesterol efflux. METHODS: Abca1-mediated cholesterol efflux was evaluated by a radioisotopic technique in mouse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter 1
Share to Cholesterol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipoproteins, LDL

Share to Liver X Receptors

Share to Macrophages, Peritoneal

Share to Proprotein Convertase 9

Share to Receptors, LDL

Share to Retinoid X Receptors

Source

Identifiers

PMID: 27940374
DOI: 10.1016/j.atherosclerosis.2016.11.019

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages.PMID 27940374Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read ↗

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.Semantic proximity Read ↗

Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity Read ↗

PCSK9 Inhibitors: Pharmacology and Therapeutic PotentialSemantic proximity Read ↗

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read ↗

PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expressionSemantic proximity Read ↗

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.